APTO Aptose Biosciences Inc

Price (delayed)

$1.8

Market cap

$14.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.93

Enterprise value

-$539,539

Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics ...

Highlights
The debt has contracted by 8% from the previous quarter
The EPS has grown by 13% year-on-year but it has declined by 2.2% since the previous quarter
Aptose Biosciences's net income has increased by 12% YoY but it has decreased by 3.5% from the previous quarter
Aptose Biosciences's equity has shrunk by 83% YoY and by 44% QoQ
The quick ratio has plunged by 74% YoY and by 27% from the previous quarter

Key stats

What are the main financial stats of APTO
Market
Shares outstanding
7.82M
Market cap
$14.07M
Enterprise value
-$539,539
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$49.25M
EBITDA
-$48.8M
Free cash flow
-$44.02M
Per share
EPS
-$7.93
Free cash flow per share
-$6.78
Book value per share
$1.19
Revenue per share
$0
TBVPS
$3.21
Balance sheet
Total assets
$20.88M
Total liabilities
$13.1M
Debt
$1.11M
Equity
$7.78M
Working capital
$7.29M
Liquidity
Debt to equity
0.14
Current ratio
1.59
Quick ratio
1.43
Net debt/EBITDA
0.3
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-143%
Return on equity
-231%
Return on invested capital
-2,022.3%
Return on capital employed
-579.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APTO stock price

How has the Aptose Biosciences stock price performed over time
Intraday
-2.7%
1 week
1.12%
1 month
-8.16%
1 year
-79.38%
YTD
-29.13%
QTD
-29.13%

Financial performance

How have Aptose Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$50.63M
Net income
-$49.25M
Gross margin
N/A
Net margin
N/A
Aptose Biosciences's net income has increased by 12% YoY but it has decreased by 3.5% from the previous quarter
The company's operating income rose by 10% YoY but it fell by 3.4% QoQ

Growth

What is Aptose Biosciences's growth rate over time

Valuation

What is Aptose Biosciences stock price valuation
P/E
N/A
P/B
1.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 13% year-on-year but it has declined by 2.2% since the previous quarter
Aptose Biosciences's equity has shrunk by 83% YoY and by 44% QoQ
The price to book (P/B) is 51% less than the 5-year quarterly average of 3.1 and 25% less than the last 4 quarters average of 2.0

Efficiency

How efficient is Aptose Biosciences business performance
APTO's return on equity has dropped by 149% year-on-year and by 51% since the previous quarter
The return on assets has dropped by 76% year-on-year and by 31% since the previous quarter

Dividends

What is APTO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APTO.

Financial health

How did Aptose Biosciences financials performed over time
The total assets is 59% greater than the total liabilities
The quick ratio has plunged by 74% YoY and by 27% from the previous quarter
The company's current ratio has shrunk by 71% YoY and by 25% QoQ
The debt is 86% less than the equity
Aptose Biosciences's equity has shrunk by 83% YoY and by 44% QoQ
APTO's debt to equity has surged by 56% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.